Epstein-Barr virus antigen-derived peptide-MHC complex (EBV pMHC)

The Epstein-Barr virus (EBV) antigen-derived peptide-MHC complex is a molecular target formed by the presentation of viral protein fragments on the surface of host cells via Major Histocompatibility Complex (MHC) molecules. These complexes, derived from latent antigens such as EBNA1, LMP1, and LMP2 or various lytic proteins, are recognized by the T-cell receptors (TCRs) of CD8+ and CD4+ T cells, triggering a targeted immune response against infected or malignant cells. In the context of EBV-associated diseases, including nasopharyngeal carcinoma, Hodgkin's lymphoma, and post-transplant lymphoproliferative disorder (PTLD), these pMHC complexes serve as the primary targets for advanced immunotherapies. Therapeutic strategies include the use of adoptive EBV-specific T-cell (VST) transfers, such as the approved drug tabelecleucel, and experimental T-cell receptor-engineered T-cell (TCR-T) therapies. A significant challenge in targeting these complexes is the virus's ability to evade the immune system by downregulating MHC expression or utilizing specialized protein domains, like the Gly-Ala repeat in EBNA1, to inhibit proteasomal processing. Additionally, therapeutic safety must account for potential cross-reactivity with human self-peptides (molecular mimicry) and the risk of graft-versus-host disease in allogeneic cell therapy settings.

Other names

EBV peptide-MHC complexEBV pMHCEpstein-Barr virus T-cell epitopesEBV-derived HLA-restricted peptidesEBV antigen-MHC complex

Adoptive cellular immunotherapy (recognition of pMHC by T-cell receptors), T-cell receptor-engineered T-cell therapy (TCR-T), and peptide-based vaccination to induce pMHC-specific T-cell responses.